国产成人三级网址在线看_日韩高清在线毛片_精品国内自产拍在线观看尤物_欧美精品 亚洲日韩_成人黄色影片在线看_国产一区二区播放_国产午夜理论最新电影_日本伊人久久综合_亚洲国产网站视频在线播放_日韩人妻系列无码专区

抗凝血酶(AT)活性蛋白

Active Antithrombin (AT)

AT3; ATIII; SERPINC1; Anti-Thrombin Antibodies; Serpin Peptidase Inhibitor Clade C Member 1; Coding Sequence Signal Peptide Antithrombin Part 1

  • 抗凝血酶(AT)活性蛋白 產(chǎn)品包裝(模擬)
  • 抗凝血酶(AT)活性蛋白 產(chǎn)品包裝(模擬)
  • APC313Hu01.jpg Figure. SDS-PAGE
  • Certificate 通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證

活性實(shí)驗(yàn)

Antithrombin III, also known as Serpin C1, is a member of the Serpin superfamily of the serine protease inhibitors. It is the principal plasma Serpin of blood clotting proteases and inhibits thrombin as well as several factors such as Xa. Similar to Serpins A5 and D1, its thrombin inhibitory activity is enhanced by heparin. Hereditary and acquired Serpin C1 deficiency is the cause of an increased thrombotic tendency in many cases. For example, acquired Serpin C1 deficiency is a common condition in sepsis, after major trauma or surgery. The activity of recombinant human antithrombin III was measured by its ability to inhibit thrombin cleavage of a fluorogenic peptide substrate Boc-VPR-AMC in the assay buffer 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% (w/v) Brij-35, pH 7.5. Thrombin was diluted to 0.5 U with heparin at 50 μg/ml in the assay buffer and 10 ul different concentrations of recombinant human antithrombin III (MW: 50 KD) was incubated with 10 ul diluted thrombin at 37 ℃ for 30?minutes. Loading 50?μL of the incubated mixtures which were diluted five-fold in assay buffer into empty wells of a plate, and start the reaction by adding 50?μL of 200?μM substrate. Include a substrate blank containing 50?μL of assay buffer and 50?μL of 200?μM substrate. Then read at excitiation and emission wavelengths of 380 nm and 460 nm, respectively, in kinetic mode for 5 minutes. The result was shown in Figure 1 and it was obvious that recombinant human antithrombin III significantly decreased thrombin activity. The inhibition IC50 was <8 nM.

用法

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

儲(chǔ)存

避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月,-80°C不超過(guò)12個(gè)月。

穩(wěn)定性

熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。

相關(guān)產(chǎn)品

編號(hào) 適用物種:Homo sapiens (Human,人) 應(yīng)用(僅供研究使用,不用于臨床診斷!)
NPC313Hu01 抗凝血酶(AT)天然蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
APC313Hu01 抗凝血酶(AT)活性蛋白 Cell?culture;?Activity?Assays.
RPC313Hu03 抗凝血酶(AT)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
EPC313Hu61 抗凝血酶(AT)真核蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
RPC313Hu01 抗凝血酶(AT)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
RPC313Hu02 抗凝血酶(AT)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
APC313Hu61 抗凝血酶(AT)活性蛋白 Cell?culture;?Activity?Assays.
PAC313Hu01 抗凝血酶(AT)多克隆抗體 WB; IHC; ICC; IP.
PAC313Hu02 抗凝血酶(AT)多克隆抗體 WB; IHC; ICC; IP.
PAC313Hu03 抗凝血酶(AT)多克隆抗體 WB; IHC; ICC; IP.
LAC313Hu81 抗凝血酶(AT)多克隆抗體(異硫氰酸熒光素標(biāo)記) WB; IHC; ICC; IF.
LAC313Hu71 抗凝血酶(AT)多克隆抗體(生物素標(biāo)記) WB; IHC; ICC.
MAC313Hu21 抗凝血酶(AT)單克隆抗體 WB; IHC; ICC; IP.
MAC313Hu27 抗凝血酶(AT)單克隆抗體 WB,IHC
MAC313Hu29 抗凝血酶(AT)單克隆抗體 WB; IHC; ICC; IP.
MAC313Hu23 抗凝血酶(AT)單克隆抗體 WB; IHC; ICC; IP.
MAC313Hu24 抗凝血酶(AT)單克隆抗體 WB; IHC; ICC; IP.
MAC313Hu26 抗凝血酶(AT)單克隆抗體 WB; IHC; ICC; IP.
MAC313Hu22 抗凝血酶(AT)單克隆抗體 WB,IHC
MAC313Hu28 抗凝血酶(AT)單克隆抗體 WB; IHC; ICC; IP.
MAC313Hu25 抗凝血酶(AT)單克隆抗體 WB; IHC; ICC; IP.
FAC313Hu02 抗抗凝血酶(AT)單克隆抗體 FCM
FAC313Hu04 抗抗凝血酶(AT)單克隆抗體 FCM
FAC313Hu08 抗抗凝血酶(AT)單克隆抗體 FCM
LAC313Hu72 抗凝血酶(AT)單克隆抗體(生物素標(biāo)記) WB; IHC; ICC.
LAC313Hu82 抗凝血酶(AT)單克隆抗體(異硫氰酸熒光素標(biāo)記) WB; IHC; ICC; IF.
SEC313Hu 抗凝血酶(AT)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) Enzyme-linked immunosorbent assay for Antigen Detection.
SCC313Hu 抗凝血酶(AT)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) Chemiluminescent immunoassay for Antigen Detection.
LMC313Hu 抗凝血酶(AT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) FLIA Kit for Antigen Detection.
KSC313Hu01 抗凝血酶(AT)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) Main materials for "Do It (ELISA Kit) Yourself".

參考文獻(xiàn)

雜志 參考文獻(xiàn)
Thromb Res Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitro [PubMed: 25840743]
Neurotherapeutics iTRAQ-Based Quantitative Proteomics Reveals the New Evidence Base for Traumatic Brain Injury Treated with Targeted Temperature Management [pubmed:29247448]
Journal of?Clinical?and Aesthetic Dermatology Detection of Angiotensin II and AT1 Receptor Concentrations in Keloid and Hypertrophic Scar. []
博士論文 An Agile Approach to Novel Recombinant Antithrombin Production for use in Biologics Development []
留言咨詢